Every 8-K that AnaptysBio, Inc. (ANAB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ANAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANAB filings page.
AnaptysBio, Inc. held its 2026 Annual Meeting of Stockholders on August 11, 2026 and reported the results of four proposals. Two Class III directors, Hollings Renton and John P. Schmid, were elected to three-year terms expiring at the 2029 annual meeting. Renton received 15,304,522 shares for and 6,613,642 withheld/abstaining votes, while Schmid received 20,314,669 shares for and 1,603,495 withheld/abstaining votes; each proposal had 2,084,465 broker non-votes. Stockholders ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending June 30, 2027, with 22,343,352 shares for and 1,640,401 against. They also gave non-binding advisory approval to named executive officer compensation with 21,274,791 shares for and approved an amendment to the 2017 Equity Incentive Plan with 15,563,882 shares for.
AnaptysBio, Inc. entered into a sublease agreement with First Tracks Biotherapeutics covering approximately 45,057 rentable square feet at 10770 Wateridge Circle in San Diego, space that AnaptysBio leases under an existing master lease.
The sublease began on June 15, 2026 and runs for 12 months, with First Tracks paying the same monthly Basic Rent and Additional Rent that AnaptysBio owes under the master lease, plus charges for any extra services it requests. AnaptysBio remains responsible to the master landlord for all lease obligations while First Tracks agrees to comply with master lease terms.
First Tracks may renew the sublease after the initial term for a period lasting until the earlier of April 4, 2028 or 12 months from the renewal start, and it can terminate at any time with at least three months’ written notice. The sublease is subordinate to the master lease and automatically ends if AnaptysBio’s master lease tenancy or possession ends.
AnaptysBio, Inc. is providing tax information to its stockholders about the dividend they received from the separation and spin-off of First Tracks Biotherapeutics, Inc. The company has filed IRS Form 8937 and is making the same information available in the Investors section of its website.
The Form 8937 explains how the spin-off dividend is treated for tax purposes and how stockholders should determine their adjusted tax basis. AnaptysBio emphasizes that this material is for informational purposes only and urges stockholders to consult their own tax advisors about their specific situations.
AnaptysBio, Inc. is changing its fiscal year-end from December 31 to June 30, as approved by its board of directors on May 18, 2026. The next fiscal year will begin on July 1, 2026.
The company will file a transition Form 10-KT covering the six-month period from January 1, 2026 through June 30, 2026, then begin filing quarterly reports based on the new fiscal year, starting with the quarter ending September 30, 2026.
AnaptysBio, Inc. reported first-quarter 2026 results and highlighted its transition to a royalty-focused business following the spin-off of First Tracks Biotherapeutics. The company now manages financial collaborations for Jemperli with GSK and imsidolimab with Vanda, targeting an EBIT margin greater than 95% with streamlined operations.
Collaboration revenue was $25.6 million for the quarter, down from $27.8 million a year earlier, as prior Vanda license revenue rolled off but Jemperli royalties grew 44% from $17.2 million to $24.7 million. AnaptysBio posted a net loss of $52.9 million, or $1.84 per share, compared with a $39.3 million loss in the prior-year period.
Cash, cash equivalents and investments totaled $286.5 million as of March 31, 2026, versus $311.6 million at year-end 2025. The company announced a $100 million stock repurchase plan expiring December 31, 2026, and continues to carry a liability of $263.7 million related to the sale of future Jemperli royalties. Management reiterated expectations of more than $390 million in annualized Jemperli royalties payable to AnaptysBio as early as 2029 based on GSK’s peak sales guidance, and noted a December 12, 2026 FDA target action date for imsidolimab in generalized pustular psoriasis.
AnaptysBio, Inc. appointed Christopher M. Murphy as Chief Financial Officer effective May 11, 2026, serving as an independent contractor under a consulting agreement. He will receive monthly consulting fees of $42,916.66, an annual target cash bonus opportunity of up to 40% of total annual consulting fees, and an equity grant valued at $1,750,000 in restricted stock units vesting over four years.
If the agreement is terminated without cause, he is eligible for nine months of continued fees, or twelve months plus bonus-related payments and full vesting of equity awards if this occurs in connection with a qualifying corporate transaction. The Board also appointed Owen Hughes as a Class I director effective May 11, 2026, with an initial grant of 11,250 restricted stock units vesting over three years.
AnaptysBio, Inc. completed the spin-off of its biopharma operations into First Tracks Biotherapeutics, Inc. on April 20, 2026 and is now providing unaudited pro forma financial information reflecting the company after this separation.
The pro forma balance sheet as of December 31, 2025 shows a $100.0 million initial cash distribution to First Tracks, reducing AnaptysBio’s cash and cash equivalents from $238,196 to $138,196 (in thousands). Pro forma 2025 results convert a historical net loss of $13,232 (in thousands) into net income of $114,857 (in thousands), with collaboration revenue of $234,603 (in thousands) and basic pro forma earnings per share of $3.99.
Notes explain that First Tracks is treated as discontinued operations under ASC 205, that AnaptysBio anticipates approximately $7.0 million of additional non-recurring spin-off costs, and that a transition services agreement will add about $2.0 million to general and administrative expenses.
AnaptysBio, Inc. completed the spin-off of its former biopharma operations into First Tracks Biotherapeutics, creating a focused royalty management company. Shareholders received one share of First Tracks common stock for every one share of AnaptysBio common stock held on the April 6, 2026 record date. First Tracks now trades on Nasdaq under “TRAX,” while AnaptysBio continues under “ANAB.”
Post-spin, AnaptysBio retains the royalty management business, exclusively overseeing financial collaborations for Jemperli with GSK and imsidolimab with Vanda. Management highlights a virtual model with limited staff, minimal operating expenses and a targeted greater than 95% EBIT margin. The parties entered into a detailed Separation and Distribution Agreement and a Transition Services Agreement governing asset and liability allocations, shared IP, tax matters and up to two years of transition services. The spin-off also triggered board resignations and executive transitions, including the Chief Medical Officer moving to First Tracks and the CEO serving AnaptysBio via a consulting agreement.
AnaptysBio is executing a major restructuring built around spinning off First Tracks Biotherapeutics and returning capital to shareholders. The board approved a pro rata spin-off of First Tracks, with holders of AnaptysBio stock receiving one First Tracks share for each AnaptysBio share held on April 6, 2026, with distribution expected before U.S. market open on April 20, 2026 and First Tracks trading on Nasdaq under “TRAX.”
To fund the new company, First Tracks and EcoR1 Capital agreed to a $145 million private placement at $13.81 per share, including 5,791,478 primary shares generating about $80 million in gross proceeds for First Tracks and 4,705,576 secondary shares sold by EcoR1. AnaptysBio also terminated its prior at‑the‑market equity program and authorized a stock repurchase plan of up to $100 million. Governance changes include appointing Susannah Gray as a director and putting executive transition and separation agreements in place for Dennis Mulroy and Eric Loumeau tied to the spin-off.
AnaptysBio plans to separate its biopharma operations into a new public company, First Tracks Biotherapeutics, in Q2 2026, while the existing company will focus on managing royalty streams from Jemperli with GSK and imsidolimab with Vanda. A Form 10 for the spin-off has been filed, and leadership and board line-ups for First Tracks are outlined.
For Q4 2025, collaboration revenue rose to $108.2 million and AnaptysBio generated net income of $49.6 million, versus a loss a year earlier, driven largely by Jemperli milestones and higher royalties. For 2025, collaboration revenue reached $234.6 million, with a narrowed net loss of $13.2 million. Cash, cash equivalents and investments were $311.6 million as of December 31, 2025, after repurchasing 3.44 million shares under a $175 million program.
AnaptysBio, Inc. filed a current report to highlight preliminary year-end liquidity it plans to share at the 2026 J.P. Morgan Healthcare Conference. The company expects to report that it had cash, cash equivalents and investments of approximately $310 million as of December 31, 2025.
The figure is described as preliminary and unaudited, and may change once normal year-end closing procedures and the independent audit are completed. AnaptysBio notes that its audited financial statements for the year ended December 31, 2025 are not yet available and that additional information will be needed for a full picture of its financial position and results. The conference presentation containing these details is being furnished as an exhibit and is explicitly not deemed filed for liability purposes under the securities laws.
AnaptysBio, Inc. reported that its Board of Directors authorized an amendment to its Stock Repurchase Plan, allowing the company to repurchase up to an additional $100.0 million of its outstanding common stock. This expands the capital return program beyond the existing authorization.
As of November 20, 2025, $6.4 million remained available under the current $75.0 million Stock Repurchase Plan. The company has already repurchased 3,443,188 shares of common stock, representing 11.2% of shares outstanding before the start of the plan, signaling a significant reduction in its share count over time.
AnaptysBio filed an 8-K noting two communications updates. The company furnished an updated corporate investor presentation as Exhibit 99.1 under Item 7.01 (Regulation FD), which is not deemed “filed” under the Exchange Act. It also filed a press release as Exhibit 99.2 under Item 8.01 announcing top-line Phase 2 data in ulcerative colitis for rosnilimab.
The filing lists Exhibits 99.1 (November 2025 presentation), 99.2 (press release dated November 10, 2025), and 104 (cover page XBRL). No financial results or transactional terms are included in this excerpt.
AnaptysBio (ANAB) furnished an 8-K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025. The release is attached as Exhibit 99.1 dated November 4, 2025.
The Item 2.02 information, including Exhibit 99.1, is furnished and not deemed “filed” and is not incorporated by reference except as expressly stated in future filings. An inline XBRL cover page is included as Exhibit 104.
AnaptysBio, Inc. (ANAB) filed a Form 8-K announcing that on October 14, 2025 it will host a conference call to discuss ANB033 and use a slide presentation during the call. The company also updated its corporate investor presentation on the same date.
Both presentations are furnished under Regulation FD as Exhibits 99.1 and 99.2 and, as stated, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference except as expressly set forth by specific reference.
AnaptysBio's board has approved plans to explore separating its business into two independent, publicly traded companies. The company says the separation is expected to occur by the end of 2026. Management will host a conference call using a slide presentation to discuss the potential separation; the presentation is included as an exhibit. A press release describing the board action is also attached as an exhibit. The disclosure notes that the Item 7.01 information and the presentation are not deemed "filed" for Section 18 purposes.